Expert committee on Covid-19 vaccine administration to meet on Wednesday

The Serum Institute of India, Pune has also been permitted for conducting Phase 2 and 3 human clinical trials of the Oxford University-developed Covid-19 vaccine

Coronavirus, Coronavirus tests
A health worker in personal protective equipment (PPE) collects a sample using a swab from a girl at a local health centre to conduct tests for the coronavirus disease (COVID-19), amid the spread of the disease at Ajmeri Gate area, in Delhi on Frida
Press Trust of India New Delhi
2 min read Last Updated : Aug 11 2020 | 11:45 AM IST
An expert committee under the chairmanship of NITI Aayog member Dr VK Paul will meet on Wednesday to consider the logistics and ethical aspects of procuring and administering the Covid-19 vaccine, the Union Health Ministry said on Tuesday.

The committee on vaccine administration will engage with all the stakeholders including state governments and vaccine manufacturers, the ministry said in a tweet.

The committee would chalk out strategies on the aspects of prioritisation of the vaccine administration once it is developed, rollout, and cold chain logistics and training of the people who would be administering it.

"The Expert Committee on Vaccine Administration under the chairmanship of Dr. V K Paul, NITI Aayog will meet on 12th August to consider logistics & ethical aspects of procurement & administration of Covid-19 vaccine," the ministry tweeted.

The phase-1 human clinical trials of the two Covid-19 vaccine candidates, developed indigenously by Bharat Biotech in collaboration with the Indian Council of Medical Research and Zydus Cadila Ltd, have been completed and the trials have moved to phase 2, ICMR Director General Balram Bhargava said last Tuesday.

The Serum Institute of India, Pune has also been permitted for conducting Phase 2 and 3 human clinical trials of the Oxford University-developed Covid-19 vaccine candidate in the country.

India's Covid-19 caseload has climbed to 22,68,675 while the death-toll mounted to 45,257, according to the Health ministry data updated at 8 am on Tuesday.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusLockdownCoronavirus VaccineCoronavirus TestsSerum Institute of IndiaHealth Ministry

Next Story